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Objectives: Intrathecal drug delivery is used for the treatment of intractable spasticity, dystonia, and pain. When the symptom-
atology fails to respond to therapy, the cause could be failure of the medication infusion. The purpose of this study is to assess
pump catheter access port (CAP)-myelography and CAP-CT-myelography as advanced imaging methods in treatment failure.
Materials and Methods: We analyzed observational routinely collected data of 70 CAP procedures with 2D/3D reconstruc-
tions and additional imaging of 53 adult patients where the cause of treatment was unclear between November 2013 and
November 2018. CAP-myelography and CAP-CT myelography were performed with postprocessing 2D/3D reconstructions.
When myelography could not be obtained or when the result did not reveal the cause of the treatment failure, additional pro-
cedures, such as noncontrast CT, MRI, lumbar puncture CT, and 111Indium-DTPA SPECT-CT, were performed.
Results: CAP fluid aspiration prior to contrast medium injection was not possible (N = 17). In one case, contrast was injected into
the pump pocket unintentionally (N = 1). Of 70 procedures, 24% were unaspiratable. The remaining CAP myelography examina-
tions (N = 52) had limited value for the diagnosis. CAP-CT myelography (N = 50) was normal (N = 31). The abnormal results
(N = 19) were dorsal dural leak (N = 5), subdural catheter position (N = 2), limited rostral flow of contrast material (N = 4), limited
and abnormal contrast distribution (N = 3), obstruction of rostral flow (N = 2), a leak at the pump-catheter connection (N = 1),
and a sheared catheter localized in the pump pocket (N = 2). Limited contrast distributions were found to be false positive find-
ings (N = 2). Four normal CT-CAP myelographic procedures were false negatives, as the reference tests revealed a cause of intra-
thecal drug delivery (ITDD) failure. The CAP-CT procedures resulted in a sensitivity of 81% (17/21) and a specificity of
93% (27/29).
Conclusions: CAP-CT myelography with 2D/3D reconstructions is an essential step in the diagnostic algorithm for cases involv-
ing ITDD failure.
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INTRODUCTION
Several observational studies demonstrate the value of intrathe-
cal drug delivery (ITDD) for therapy-resistant spasticity, dystonia,
and pain (1–3). Older data show a high complication rate, mainly
related to the intrathecal catheter, with this rate varying widely
among treating specialists (4–7). Current complications are related
to the handling of the delivery system itself, as well as to its
implantation or the underlying condition of the patient. As result
of catheter improvements, the complication rate seems to have
been considerably reduced (8,9).
Based on referred patients, we conclude that, in ITDD failures,
advanced imaging procedures are frequently not performed or
performed inadequately, which can lead to undertreatment,
unnecessary surgery, or even unjustified termination of therapy.
Algorithms for troubleshooting and the involved diagnostic pro-
cedures are subject to debate. One topic in this discussion is the
role of catheter access port (CAP) computed tomography
(CT) myelography as an advanced diagnostic procedure. Saulino
et al (10) stated that the CAP-CT procedure should be part of the
standard approach. However, it was recently suggested that the
use of this procedure should be limited to emergencies and that
it should not be considered as a routine examination (11). The
aspiration failure rate of the CAP puncture, the nonphysiological
flow of contrast material in the intrathecal space, the probable
lower costs, and the lower radiation dose of 111Indium-diethylene-
triamine-penta-acetic acid scintigraphy (111In-DTPA) single-photon
emission CT (SPECT-CT) were presented as arguments (11).
Application of additional SPECT-CT imaging to the planar scinti-
graphic images led to improvement, but clinical experience is lim-
ited (12–14), and the interpretation of leakage thus does not
seem to be precise (15). Nevertheless, SPECT-CT, which allows for
the anatomical localization of a disorder, is essential when scintig-
raphy is applied. However, low-dose energy SPECT-CT will lead to
a lower quality of imaging in comparison with CAP-CT
myelography. In our opinion, 111In-DTPA SPECT-CT and CAP-CT
myelography are not entirely comparable. Both have a place in
the ITDD troubleshooting algorithm, and the choice of procedure
seems to be more a matter of preference concerning the
sequence in the algorithm. The dynamic character of scintigraphy
offers the unique possibility of following the tracer distribution
over a time frame of several days and determining the location of
the problem but has the issue that 111In-DTPA radioactive sub-
stance is unavailable in an emergency. CAP-CT myelography with
more high-resolution imaging could be crucial in determining the
location and magnitude of the disorder. Although both proce-
dures have been performed for several decades, published data
are scant and it is unclear how many patients have undergone
111In-DTPA SPECT-CT or, to the best of our knowledge, even
absent for CAP-CT myelography. The consequence is a lack of a
consensus regarding the optimal procedures and diagnostic
criteria for determining ITDD failure (16). A comparison of the two
methods could only be made with the same patients and after
extensive evaluation and is therefore beyond the scope of this
report.
The CAP procedure is not always easy to perform, which could
be one of the reasons for its omission from the standard diagnostic
approach. Technical skills, the position of the implanted pump, the
possible presence of severe fibrotic reaction around the pump, and
the vulnerable needle for CAP puncture are relevant factors. In
ITDD failures, advanced imaging procedures are frequently not
performed or are performed inadequately, which can lead to
undertreatment, unnecessary surgery, or even unjustified termina-
tion of therapy. Over the last few years, we have routinely used
CAP myelography and fluoroscopy, combined with CT and 2D mul-
tiplanar reformation (MPR) (17), 2D maximum intensity projection
(MIP) (17), and 3D volume-rendering technique (VRT) (17) recon-
structions, in troubleshooting. The intended use of the CAP-CT
procedure was to diagnose catheter leaks or obstruction or abnor-
mal rostral distribution of the injected contrast material. The moti-
vation for this retrospective observational study focused on
routinely collected data was the paucity of information concerning
the performance and the results of CAP (CT) myelography. There-
fore, we aimed to assess the value of and the various factors
involved in maximizing the diagnostic use of CAP (CT) myelography
as an advanced imaging method in ITDD troubleshooting. The
primary approach was the analysis of the application of CAP
(CT) myelography in ITDD troubleshooting. When the procedure did




We included all routinely collected data from 70 CAP
(CT) myelography procedures in 53 adult patients who were eval-
uated for ITDD failure between November 2013 and November
2018. Fifty-two of the patients were referred to our hospital for
ITDD troubleshooting, when the referring neuromodulation center
could not solve the problem of ITDD treatment failure. Our diag-
nostic procedures were prompted by the suspicion that the ther-
apy was suboptimal or absent in its effect, leading us to question
the efficacy of drug delivery. In all patients, a SynchroMed II pump
model 8637 was implanted in the abdominal region together with
the associated intrathecal catheters (Type 8731SC or Ascenda
8780/8781) (Medtronic Inc., Minneapolis, MN, USA). The lack of
precise information concerning the pump and catheter applica-
tion of the referred patients did not allow investigation of the
incidence of their complication rate in a time frame. CAP-
(CT) myelography was considered in treatment failure with severe
symptomatology (18). In mild cases, the procedure was performed
when the failure could not be managed with dose adaptations by
a bolus administered by the pump or a lumbar puncture (18) in
combination with conservative nonpharmaceutical treatment.
Furthermore, a requirement was that the cause was not identi-
fied as being related to the patient’s history, a signaled pump
failure or a programming error in the pump readout, an unex-
pectedly empty pump, or abnormal plain radiography. ITDD
failure was defined as the presence of one or more of the
following criteria: a decrease in effectiveness of treatment,
discrepancies between accurate aspirated volume versus inter-
rogated reservoir volume, manifest- or occult-drug cerebrospi-
nal fluid (CSF) leakage, repeated dosage increases without
clinical improvement, and dosages exceeding 50% of the maxi-
mum recommended dosage with an insufficient clinical result
(19,20). The first and last authors reexamined the images, taking
all clinical features into consideration. Their assessments were
focused on the distribution of the contrast medium injected via
the CAP, the pump shape, catheter-pump connections, the
course of the catheter, the catheter-catheter connection, the
dural insertion, and the intrathecal distribution. When CAP2
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(CT) myelography did not reveal the diagnosis or when there
was doubt concerning it, we carried out additional imaging pro-
cedures and discussed their results. The majority of other proce-
dures involved 111In-DTPA SPECT-CT scintigraphy. The study
was approved by the medical ethics committee of our center
(MEC-2017-326); in addition, given that this study is based on
routinely collected procedure data that were retrospectively
analyzed, meaning that the study had no impact on the patient,
the requirement to obtain informed consent was waived.
CAP Myelography
CAP insertion using a 24-G non-coring Huber needle was per-
formed under fluoroscopy under strictly sterile conditions. We
found that, with the template provided with the CAP kit (Model
8540; Medtronic Inc.), the CAP funnel position could not be recog-
nized in all cases. During fluoroscopy, we use a metal object
(e.g., a surgical clamp or a pair of tweezers) to determine the CAP
funnel’s location. We positioned the C-arm fluoroscopy device
such that the beam was parallel to the CAP axis, which allowed
perpendicular needle insertion into the funnel. To prevent an
injection overdose caused by the flushing of the highly concen-
trated catheter content into the intrathecal space, we first aspi-
rated 2 mL of fluid (21). When we could not aspirate, we omitted
the contrast material injection and terminated the procedure or
when not performed previously, a noncontrast CT scan. After suc-
cessful fluid aspiration, we injected 10 mL of contrast material
(iohexol, Omnipaque 300, GE Healthcare B.V., Eindhoven, The
Netherlands). Due to the high viscosity of the contrast material
and the small needle diameter, we had to apply significant force
during the injection. To reduce the force required, the contrast
material was injected at body temperature. To ensure an optimal
distribution of the contrast material in the CSF, we turned the
patient to the left and to the right and placed him or her in
the Trendelenburg position. Under fluoroscopy, we controlled the
catheter pathway for leakages and the accurate intrathecal distri-
bution of the contrast material. Thereafter, we performed a
myelogram. Next, we flushed the catheter with 2 mL preservative-
free saline fluid to remove the contrast material from the catheter.
To prevent a withdrawal syndrome, we programmed the pump
for a catheter-priming bolus injection, which was calculated based
on the catheter length and drug concentration.
CAP-CT Myelography
Following CAP myelography, we performed a CT scan. The first,
and largest, group of patients was evaluated using a single-energy
CT (SECT) scanner. Prior to the CAP procedure, we implemented
low-dose single-energy CT with postprocessing 2D/3D reconstruc-
tions with a low radiation exposure as a replacement for postoper-
ative and noncontrast troubleshooting procedures, as recently
suggested (22). This technique allows visualization of the entire
drug delivery pathway. Catheter-related problems such as discon-
nection, dislocation, kinking, or twisting can be identified. However,
for CAP-CT myelography, we need more precise information
and used standard high-dose CT. We have recently switched from
single-energy CT to dual-energy CT when applying this CT
procedure (23). Therefore, we used the twin-beam dual-energy
CT scan (Siemens Healthcare GmbH, Erlangen, Germany) with gold
(Au) and tin (Sn) filters in combination in front of the 120 kVp X-ray
beam (24). The filters split the beam into high- and low-energy X-
ray spectra before it reaches the patient. Further image
improvement could be achieved with a metal artifact reduction
algorithm (iMAR). The different x-rays provide dual-energy CT a fur-
ther advantage over single-energy CT by providing more informa-
tion when metal implants (e.g., the pump, catheter-catheter
connector, or osteosynthesis material) are present in the scanned
area. With this approach, the scattering caused by the metal parts
could be reduced. Furthermore, leaks at the catheter-catheter and
the pump–catheter connection could be distinguished from beam-
hardening artifacts. Originally, we limited the reconstructed scan
field of view to the spine. To obtain information concerning the
entire implanted drug delivery system from the dorsal to the
abdominal pump-implanted area, we extended the field of view to
the extra-vertebral abdominal region. For the imaging of the intra-
thecal catheter and the distribution of the contrast material above
the catheter tip, we applied a lumbar-cervical spine scan range. A
breath-holding command was given to avoid pump movement
during breathing. The scan parameters for dual-energy CT included
the following: collimation: 300 × 0.6 mm; rotation time: 0.5 sec; and
slice thickness: 0.8 mm. Although radiation exposure is crucial in
CAP-CT myelography, the use of dual-energy with a higher radia-
tion load instead of the original single-energy CT does not out-
weigh the importance of precise imaging. To further improve CAP-
CT myelography imaging, we postprocessed the data on a worksta-
tion to 12-mm maximum intensity projections (17), which enables
the imaging of highly intensive structures with respect to the sur-
rounding structures, and to 1.5 mm multiplanar reformations (17),
whereby thin-slice axial data were converted into coronal, sagittal,
oblique, or curved planes, which allows one to follow the course of
the implanted catheter. Using the volume-rendering technique
(17), we transformed the axial data into 3D images.
Additional Imaging Procedures
In this study, when we could not aspirate CSF via the CAP and
CAP(-CT) myelography was consequently not permitted, we still ful-
filled the scheduled CT as a standard noncontrast CT to identify an
epidural catheter. When the epidural catheter position was not clear,
we additionally carried out lumbar puncture (LP) CT myelography.
Our next diagnostic step when CSF could not be aspirated was
111In-DTPA scintigraphy. To determine the anatomical position and
to obtain detailed information concerning the identified abnormal-
ity, we combined the planar scintigraphy with SPECT-CT. To be cer-
tain of a normal rostral intrathecal activity distribution over time, we
optimized the scintigraphy by standardizing the pump flow rate, as
result of which the tip of the intrathecal catheter would typically be
reached after 24 hours. Magnetic resonance imaging (MRI) was used
to identify localized intrathecal abnormalities.
Statistical Analysis
The sensitivity and specificity of the different procedures were cal-
culated by comparing the imaging assessment outcome as the index
test, with the outcome of the gold standard reference test, which was
based on all performed imaging procedures and clinical and surgical
information. A true-positive result was thereby defined as when an
abnormality could be demonstrated with the index test and the refer-
ence indeed revealed a cause of ITDD failure, a true negative when
no abnormality was found with the index test and the reference test,
a false positive when an estimated abnormality could not be con-
firmed by the reference, and a false negative when the abnormality
was overlooked. Due to the limited number of noncontrast CT scan
procedures, we omitted the calculations of accuracy.
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RESULTS
CAP Procedures
Table S1 summarizes the patient characteristics, the results, and
the standard references used, which were distilled from the
results. We performed 70 procedures on 53 patients. No adverse
events were reported as a result of the procedures. In 13 patients,
the method was conducted several times, which resulted in a
total of 17 additional procedures. The reasons for these additional
procedures were as follows: one patient’s spasticity was under
insufficient control and was exac0erbated after two years (N = 2),
4
Figure 1. Results when via CAP cerebrospinal fluid could not be aspirated. [Color figure can be viewed at wileyonlinelibrary.com]
Figure 2. Catheter access port CT multiplanar reformation myelography revealed a normal intrathecal 8731SC catheter tip position (a, gray arrow) and a regular
small-diameter Ascenda catheter tip position (b, gray arrow). The noncontrast CT multiplanar reformation image fostered suspicion of an epidural tip position of
the 8731SC catheter (c, gray arrow). LP CT myelography confirmed the epidural position (d, gray arrow). CAP-CT multiplanar reformation myelography showed
extensive subdural (e, black arrow) and minimal intrathecal (e, white arrow) contrast material, which explained the irregular contrast material distribution found
with CAP myelography (Fig. 5c).
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a persistent leak (N = 2), an unexplained reoccurrence of treat-
ment failure (N = 2), a persistent treatment failure (N = 8), a lim-
ited effect after the surgical intervention (N = 1), to control a
surgical intervention (N = 1), and when a broken catheter was
replaced (N = 1).
CAP CSF Aspiration
In 17 procedures, we could not aspirate the CSF (Fig. 1), and
contrast material was therefore not injected via the CAP. In nine
of the 17 patients (53%) in which CSF aspiration was not possible,
revealed a functional catheter based on scintigraphy with normal
tracer distribution (N = 5), MRI with no abnormalities (N = 2), and
a successful dose adaption (N = 2). Noncontrast CT scans showed
an epidural catheter position (N = 4, Fig. 2c), which was confirmed
by LP-CT myelography (N = 1, Fig. 2d), a downwards curved intra-
thecal catheter (N = 1), and normal findings (N = 3). 111In-DTPA
SPECT-CT demonstrated CSF flow obstruction (N = 2). Of the
patients who refused further diagnostic procedures, one was
suspected to have catheter obstruction but wished to terminate
the therapy.
CAP Myelography
In 53 procedures, we injected the contrast material via a needle
positioned in the CAP (Fig. 3). Myelography could not be per-
formed due to an unintended injection into the pump pocket
(N = 1, Fig. 4a). Of the remaining 52 CAP-myelographies, 36 were
normal. Sixteen revealed a suspected pump-catheter-related
cause of ITDD failure, including catheter leak (N = 2, Fig. 5a), a
downward curved catheter with possible reduced flow (N = 1),
limited abnormal contrast distribution (N = 6, Figs. 5b,c), an acute
stop in the contrast distribution (N = 2, Fig. 3d), and a limited
normal-shaped contrast distribution (N = 5, Fig. 5e). In 12 of these
16 CAP myelographic procedures, the reference tests revealed a
cause of ITDD failure, while, in four procedures, the limited con-
trast distribution (N = 3) and a downward curved catheter with
possible reduced flow (N = 1) were found to be false positive find-
ings. Eleven normal CAP myelographic procedures were false
5
Figure 3. Results of catheter access port myelography. [Color figure can be viewed at wileyonlinelibrary.com]
Figure 4. Scattering on catheter access port CT multiplanar reformation (gray arrow) images caused by contrast material in the pump pocket. At the procedure,
7 mL of contrast material was unintentionally injected into the pump pocket (a). A sheared catheter located in the pump pocket caused contrast material accu-
mulation (b). Severe CSF and contrast material appearance in the pump pocket (c) as a result of a dorsal dural leak at the previous catheter insertion, where CSF
passed retrograde along the implanted catheter, and a normal pump appearance after aspiration of the fluid and dural leak treatment with an epidural blood
patch (d).
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negatives, as the reference tests revealed a cause of ITDD failure.
The calculated sensitivity of CAP myelography was 52% (12/23),
with a specificity of 86% (25/29).
CAP-CT Myelography
We carried out 50 CAP-CT myelography procedures in which
images of the spinal column were reconstructed (Fig. 6). In 24 of
these procedures, the field of view of the image reconstruction
was enlarged to the extra-vertebral region, including the abdomi-
nal pump position and the extra-spinal catheter tract. CAP-CT
myelography was diagnosed as normal (N = 31). Four of these nor-
mal CAP-CT myelographic procedures were false negatives, as the
reference tests revealed a cause of ITDD failure. The findings
included only spinal region evaluation (N = 1), while the catheter
leak was present in the extra-vertebral region. Scintigraphy (N = 3)
6
Figure 5. Catheter access port myelography revealed a pump-catheter connector leak (a, arrow), irregular distribution of the contrast material, caused by an
intradural cyst (b), subdural catheter position (c), CSF flow obstruction (catheter tip position above the obstruction) (d), and an inadequate Trendelenburg maneu-
ver (e).
Figure 6. Results of catheter access port computed tomography myelography. [Color figure can be viewed at wileyonlinelibrary.com]
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revealed a normal result (N = 1), whereby an intrathecal leak was
found during surgical intervention, a catheter obstruction (N = 1),
and a retrograde tracer distribution via a retained catheter (N = 1).
Spinal CAP-CT myelography revealed 16 suspected causes of
ITB failure, including dorsal dural leak (N = 5, Fig. 7f,g), subdural
catheter position (N = 2, Fig. 2e), limited rostral flow of contrast
material (N = 4), limited and abnormal contrast distribution
(N = 3), and obstruction of rostral flow (N = 2). The extra-vertebral
image reconstructions revealed three causes of ITDD failure,
namely contrast media around the pump owing to a leak at the
pump-catheter connection (N = 1), a sheared catheter in the
pump pocket (N = 1, Fig. 4b), and contrast material in the abdom-
inal soft tissue due to a catheter leak (N = 1, Fig. 7b,c), the latter
of which was not identified by CAP myelography (Fig. 7a). Dural
leaks (N = 5) were defined as a loss of CSF from the intrathecal
space. The loss could be postoperative or chronic and with or
without clinical symptomatology. The observed leaks were caused
by a previous catheter insertion site (N = 4, Figs. 4c and 7d,e) and
occurred after the reinsertion of a catheter (N = 1, Fig. 7f,g). In
two cases, the dural leak that was visible on the spinal CAP-CT
myelography was accompanied by retrograde flow to the pump
pocket, which was visible on the extra-vertebral image reconstruc-
tion (Fig. 4c). We could treat the dural CSF leaks with one to three
homolog epidural blood patches. In our approach, we injected
slowly over a few minutes to a maximum of 20 mL or terminated
the procedure when the patient complained of a headache.
In two procedures, a limited contrast distribution was
found, which transpired to be false positive findings. CAP-CT
myelography was normal in 31 procedures. Four normal CT-CAP
myelographic procedures were found to be false negatives, as
the reference tests revealed a cause of ITDD failure, including
one examination in which only the spinal region was evaluated
while a catheter leak was present in the extra-spinal region, one
examination in which the follow-up scintigraphy was normal, but
an intrathecal catheter leak was found during surgical interven-
tion, one examination in which scintigraphy revealed catheter
obstruction, and one examination in which scintigraphy revealed
retrograde tracer distribution via a retained catheter. The CAP-CT
procedures resulted in a sensitivity of 81% (17/21) and a specific-
ity of 93% (27/29).
DISCUSSION
Based on the analysis of the observational retrospectively col-
lected CAP and CAP-CT myelography data for troubleshooting
7
Figure 7. a, The tiny catheter leak was not recognized with catheter access port (CAP) fluoroscopic myelography (left, white arrow). CAP-CT multiplanar reforma-
tion myelography revealed abnormal subcutaneous contrast material accumulation (middle, white arrow). The 3D volume-rendering technique reconstructions
demonstrated minor catheter leak (right, white arrow). b, CAP-CT multiplanar reformation myelography showed dural leak at the original insertion of a migrated
catheter (gray arrow), with at the opposite site the newly inserted catheter (white arrow). c, CAP maximum intensity projection myelography showed minor
extradural contrast accumulation, which was caused by a small dural leak (white arrow).
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8Figure 8. Applied algorithm in intrathecal drug delivery failure.
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purposes, we confirmed the importance of CAP-CT myelography
in diagnosing the causes of ITDD failure. With CAP handling,
there is potentially the risk of intoxication should the highly
concentrated medication in the intrathecal catheter not be
completely aspirated or of withdrawal when after the procedure
the intrathecal catheter is not refilled by a programmed bolus
injection of the medication. We found that, when the algorithm
is followed, the procedure could be performed safely. Together
with the results presented in a recent publication, the data of
the study indicate the need for a revision of the algorithm used
(Fig. 8). The changes include a replacement of plain radiography
by low-dose CT with 2D/3D reconstructions in first-line trouble-
shooting. Applying this type of CT, the standard dose non-
contrast CT, which we performed when fluid could not be
aspirated via the CAP provide no additional information and
was therefore removed from our algorithm. Instead of the stan-
dard dose noncontrast CT, we will apply lumbar puncture
myelography, which offers more reliable information about an
epidural catheter and also allows for the identification of an
obstruction in the spinal canal.
CAP Procedure
The identification of a catheter obstruction, an epidural or
subdural catheter position, or a pump-catheter disconnection
where fluid could be aspirated, was potentially misleading, as it
could lead to the unjustified conclusion that a catheter is func-
tional. The respective explanations could be as follows: a partial
catheter obstruction allowed fluid aspiration; at the epidural
catheter position, the aspirated fluid was not CSF but the drug
solution; the subdural catheter position was associated with a
minor amount of intrathecal CSF; and, in a pump-catheter dis-
connection, the aspirated fluid was present in the pump pocket.
When fluid cannot be aspirated via the CAP of the pump, it does
not always indicate a catheter obstruction or a disconnection
(25), as we confirmed in nearly half of the cases. We cannot offer
a convincing explanation; perhaps it is a matter of catheter col-
lapse during aspiration or catheter holes positions close to the
dura wall. We initially terminated the CAP procedure when the
fluid could not be aspirated. When unsuccessful CAP aspiration
is aborted due to an inability to aspirate fluid, no repro-
gramming of the device needs to be performed.
CAP Myelography
This study confirmed that an appropriate diagnosis or the iden-
tification of an abnormality can often not be made with CAP fluo-
roscopy and myelography only, which limits their value when not
routinely followed by CAP-CT myelography. Therefore, the use of
CAP-CT myelography alone has been suggested (26). In addition,
in our study, the value of CAP-myelography was limited; only two
diagnoses, which were subsequently confirmed with spinal/
abdominal CAP-CT-myelography, were made. However, fluoros-
copy provides a screening overview that makes it possible to
identify sufficient intrathecal distribution of contrast material,
which is crucial for an optimal diagnostic CT myelography exami-
nation. An optimal distribution of contrast material can be
achieved through rotation and turning of the patient in different
directions, including the Trendelenburg position. An inadequate
distribution of contrast material could result in an abnormal
examination, as the limited distribution may be misinterpreted as
a CSF flow obstruction. Therefore, when fluoroscopy reveals
insufficient contrast material distribution in the intrathecal space,
the Trendelenburg maneuver should be performed again.
CAP-CT Myelography
Through the use of CT myelography extended with 2D maxi-
mum intensity projection/multiplanar reformation and 3D post-
processing reconstructions based on the volume-rendering
technique, we achieved substantial improvement in diagnostic
accuracy. The demonstrated sensitivity and specificity of the spi-
nal CT myelography examinations indicated the usefulness of the
proposed procedure. However, the extra-vertebral parts of the
ITDD system should be included in the reconstructed field of view
to detect leaks in the catheter pathway and accumulations of con-
trast material in the pump pocket and their causes. In an identi-
fied dura leak, an unexpected finding was caused by retrograde
flow of CSF and contrast material along the implanted catheter.
This observation means that, in cases of pocket fluid accumula-
tion, a dural leak should be considered. Furthermore, the symp-
tomatology of a dural leak varies from tremendous manifest
dropping CSF leak to silent, sometimes chronic, not clinically rec-
ognized dural leak with and without complaints of post-dural
puncture headache. We could manage the dural leaks with one to
three epidural homolog blood patches.
The reduction of beam-hardening artifacts when using dual-
energy CT facilitated the identification and cause of fluid in the
pump pocket and leaks at the metal catheter-catheter connection.
However, beam-hardening reduction should be used carefully
when a leak in the pump pocket, which can cause more irregular
scattering that resembles beam hardening, is suspected. A leak
may be overlooked when a strong beam-hardening reduction
algorithm is applied. With the correct beam-hardening reduction,
the observed fluid in the pump pocket makes multisession scin-
tigraphy unnecessary.
Accumulation of the contrast material in the subdural space
was observed with a faint distribution in the intrathecal space
due to a subdural catheter location was observed in only two
cases. We therefore could not confirm the reported 18.9% (12).
The limited intrathecal contrast material can explain the surprising
finding of CSF aspiration in a dural catheter position. The subdural
cavity between the meningeal layer of the dura mater and the
inner arachnoid mater of the leptomeninges, which are adherent
to each other, usually does not exist (27). A potential explanation
is unintentional separation during puncture (28,29).
In all of the patients with an unintended epidural catheter, the
cause was not a dural perforation at the tip of the catheter but an
epidural position starting at the dural insertion. Despite the epidu-
ral location, aspiration of 2 mL via the CAP was possible. It seems
that, despite low-volume infusion, epidural fluid accumulation
occurs when tissue absorption is insufficient, which is likely
related to epidural fibrosis as a result of long-term infu-
sion (30–32).
We prefer our modified dual-energy spinal/abdominal CAP-CT-
myelography as the initial step in advanced imaging algorithm
and reserved scintigraphy for the next. CAP-CT-myelography
offers excellent possibilities in terms of identifying flow obstruc-
tion, catheter kinking, and leaks, as well as the cause(s) thereof,
and a diagnosis often can be made based on a one-day proce-
dure. The latter is a major advantage for severely handicapped
patients for whom traveling is a burden. Theoretically, further
advantages are that puncturing the CAP provides an opportunity
to aspirate CSF for diagnostic microbiological and
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pharmacological examinations. CAP-CT myelography generally
provides more local information than low-dose energy 111In-DTPA
SPECT–CT. In dural and catheter leaks, the more detailed images
of CAP-CT myelography are essential in treatment. A few patients
refused further imaging procedures; the consequence was that
we had to draw our conclusions based on clinical criteria and not
on diagnostic imaging.
Additional Imaging Procedures
When we could not assess the cause of ITDD failure with CAP-
CT myelography, we proceeded with other imaging modalities. In
the study, standard noncontrast CT was helpful for the diagnosis
of epidural catheter position when fluid could not be aspirated
via the CAP and CAP-CT myelography was therefore not allowed.
When using the revised algorithm and low-dose CT, there is no
longer any reason to perform this procedure. MRI was used to
exclude granuloma formation at the tip of the catheter, and lum-
bar puncture CT myelography was used to identify CSF fluid
obstruction or when in doubt of the epidural catheter position
with standard noncontrast CT. In particular, when we needed
dynamic information concerning catheter flow or the distribution
of intrathecal contrast material, we performed modified 111In-
DTPA SPECT-CT scintigraphy.
With this modification, we standardized the flow rate to estab-
lish a norm for tracer transit time. As we found, this information is
crucial for identifying partial obstruction, as a result of which del-
ayed and/or reduced rostral visibility could be overlooked. There-
fore, we disagree with the statement that an examination is
normal when the tracer activity progresses to the cerebral cisterns
without leakage. As we observed, the clinical relevance of a partial
obstruction in CSF flow could be difficult to interpret with CAP-
CT-myelography, and the additional dynamic flow information
provided by scintigraphy could prove valuable in deciding
whether or not to carry out an intervention. We found that,
despite a limited leak, tracer activity can reach the intrathecal
space. However, the ITDD failure indicates that the amount of
medication in the CSF was probably insufficient for a successful
treatment. More publications will probably offer clarity about the
observation. After identifying normal rostral distribution with scin-
tigraphy, we accepted the finding of the curved catheter in the
intrathecal space as normal in the absence of further complica-
tions (33). Although scintigraphy was not performed in all
patients, the observed high accuracy of 111In-DTPA SPECT-CT
leaves it open to discussion whether the primary choice for ITDD
troubleshooting should be CAP-CT myelography or 111In-DTPA
SPECT CT scintigraphy (11). We prefer our modified dual-energy
CT myelography, as it offers excellent possibilities in terms of
identifying flow obstruction, catheter kinking, and leak. Further
advantages are that puncturing the CAP provides an opportunity
to aspirate CSF for diagnostic microbiological and pharmacologi-
cal examinations. For therapeutic purposes, the intrathecal cathe-
ter content can be aspirated after an overdose or for complex
dose concentration changes. Moreover, a bolus dose of the
current medication, an additional drug, or contrast material for
controlling the ITDD can be injected via the CAP. CAP-CT
myelography generally provides more local information than low-
dose 111In-DTPA SPECT-CT. In dural and catheter leaks, the more
detailed images provided by CAP-CT myelography are essential in
treatment. However, 111In-DTPA SPECT-CT is helpful when no fluid
can be aspirated via the CAP. In addition, when a normal-shaped
limited flow is identified and there is no certainty that the
Trendelenburg position has been appropriately performed, scin-
tigraphy can be used to visualize the physiologic fluid distribu-
tion. In both methods, however, identifying fluid in the pump
pocket can be an issue. In CAP-CT myelography, pump scattering
can mask the presence of fluid, although the irregular scattering
of fluid differs from that of beam hardening caused by the pump.
This problem can be overcome by reducing the scattering via
advanced CT techniques such as DECT. We found that, in 111In-
DTPA SPECT-CT, the intense tracer activity in the pump is not an
obstacle to assessing aberrant fluid in or nearby the implanted
pump with the use of image scaling and the progression of fluid
accumulation during multiple imaging sessions. Hence, we
10 Figure 9. Dual-energy catheter access port CT myelography with metal artifact reduction with irregular scattering (a, white arrow) showing fluid in pump pocket.
Additional 111Indium-DTPA scintigraphy: planar imaging (b) pump failure or leakage, SPECT (c), and CT progressive minor deformation suspect for leakage.
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disagree with those who advocate reserving the CAP-CT proce-
dure only for emergencies and using 111In-DTPA in all nonacute
situations (11). In our opinion, scintigraphy is a crucial step in the
troubleshooting algorithm when a diagnosis cannot be made
with CAP-CT myelography or when in doubt and confirmation is
required, but it does not outweigh the convenience and accuracy
of a CAP-CT myelographic procedure, even when one does not
consider the burden placed on the patient, the costs, and the low
likelihood of availability in every center. A few patients refused
further imaging procedures, with the consequence being that we
had to draw our final conclusion based on clinical criteria and not
on diagnostic imaging. The finding of a pocket leak while tracer
activity was also found in the intrathecal space was intriguing.
CAP-CT Myelography and 111Indium-DTPA Scintigraphy-
SPECT
In our opinion, CAP-CT myelography and 111Indium-DTPA scintig-
raphy are not entirely comparable. However, both have their place
in ITDD troubleshooting. With the current knowledge of and expe-
rience with dual-energy CAP-CT myelography with iMAR, the image
(Fig. 9) would be assessed as fluid in the pump pocket (see also
Fig. 4). At that time at which the image was created, there was
doubt as to whether the image indicated beam hardening or fluid
in the pocket. Additional 111Indium-DTPA scintigraphy-SPECT was
performed, which indicated the presence of fluid in the pocket, but
this finding was not completely convincing. Surgical interventional
demonstrated a sheared catheter localized in the pump pocket.
Today with our optimized CT procedure, we would not have car-
ried out additional scintigraphy. The opposite was the situation
where we identified an obstruction in the intrathecal contrast
material distribution using CAP-CT myelography. Initially, it was
concluded that the obstruction was not the reason for ITDD failure.
To ascertain normal medication delivery and the absence of bias
caused by a forced injection of contrast material, additional scintig-
raphy was performed. While performing the scintigraphy, we stan-
dardized the pump flow such that the catheter tip would be
reached at 24 hours. The observed high thoracic gradient on the
planar images and the reduced cerebral cisternal tracer activity
confirmed stagnation of distribution, and the SPECT-CT imaging
showed an almost complete intrathecal stop. While imitating nor-
mal intrathecal flow functional drug delivery hindrance could be
demonstrated with scintigraphy. We concluded that this observa-
tion was likely the cause of ITDD failure.
STUDY LIMITATIONS
The analysis of the observational routinely collected data was
intended to evaluate the diagnostic role of CAP-CT myelography
in ITDD failure and to improve the procedure by omitting high-
dose non-contrast CT, ameliorating imaging with the standard
use of dual-energy CT with metal artifact reduction, post-
processing the 2D/3D reconstructions, and evaluating its results.
A limitation is that the data analysis could not be addressed using
existing reporting guidelines such as STrengthening the Reporting
of OBservational studies in Epidemiology (STROBE) (34). Neverthe-
less, routinely collected data are frequently used to improve
patient care and health care efficiency. To our knowledge, our
study is the most extensive analysis to date; however, the sample
size is small. In addition, the retrospective character of this
research presents a chronology bias (35); how this might have
influenced our conclusions must be considered. To reduce mis-
classification bias, all images were reassessed. The most important
limitation is the unstructured approach to data collection, which
resulted in the absence of a standardized reference test based on
a second imaging modality or surgery to determine the actual
cause of ITB failure. Instead, we composed the reference based on
all available data, including the index test, additional imaging
modalities, surgery, and wait-and-see results.
CONCLUSIONS
Despite the bias in the design of this study, the data suggest
that CAP myelography followed by CAP-CT myelography are
indispensable steps in determining the causes of ITDD treatment
failure. The premises of this study are as follows:
• CAP dual-energy CT myelography with image reconstructions
of the spinal and extra-vertebral regions in combination with
2D multiplanar reformation/maximum intensity projection and
3D volume-rendering technique reconstructions is an advanced
imaging procedure for cases involving ITDD failure.
• Failure to aspirate CSF via the CAP does not indicate catheter
failure in all cases.
• Conducting CAP myelography alone is insufficient for the diag-
nosis of ITDD failure; however, it has value in facilitating needle
insertion of the CAP and as a screening method for determin-
ing sufficient distribution of the contrast material, which is cru-
cial in a diagnostic CAP-CT myelography.
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SUPPORTING INFORMATION
Additional supporting information may be found online in the
supporting information tab for this article.
COMMENT
The authors present impactful information that informs clinicians
who manage ITDDS as our specialized community in neuromodulation
moves toward more standardization in the management ITDD to
reduce variability between clinicians and ultimately improve patient
safety and outcomes.
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